Skip to main content
Erschienen in: Digestive Diseases and Sciences 4/2022

28.06.2021 | COVID-19 | Editorial Zur Zeit gratis

Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications?

verfasst von: Sara Horst

Erschienen in: Digestive Diseases and Sciences | Ausgabe 4/2022

Einloggen, um Zugang zu erhalten

Excerpt

During the year 2020, GI physicians were faced with many questions, in particular how patients with inflammatory bowel disease (IBD) would be affected by infection with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the cause of coronavirus disease 2019 (COVID-19). Research teams and organizations rapidly led intense efforts to quickly advance the understanding of the impact of COVID-19 for patients with IBD, including the formation of the Surveillance Epidemiology of Coronavirus Under Research Exclusion for Inflammatory Bowel Disease database (SECURE-IBD). This voluntary international registry enabled providers to gather and disseminate information about patients with IBD who developed a COVID-19 infection [1]. …
Literatur
1.
Zurück zum Zitat Brenner EJ, Ungaro RC, Gearry RB et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481-491 e483.CrossRef Brenner EJ, Ungaro RC, Gearry RB et al. Corticosteroids, but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an international registry. Gastroenterology. 2020;159:481-491 e483.CrossRef
2.
Zurück zum Zitat Aziz M, Fatima R, Haghbin H, Lee-Smith W, Nawras A. The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis. 2020;26:e132–e133.CrossRef Aziz M, Fatima R, Haghbin H, Lee-Smith W, Nawras A. The incidence and outcomes of COVID-19 in IBD patients: a rapid review and meta-analysis. Inflamm Bowel Dis. 2020;26:e132–e133.CrossRef
3.
Zurück zum Zitat Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX. Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? results from a nationwide veterans’ affairs cohort study. Am J Gastroenterol. 2021;116:808–810.CrossRef Khan N, Patel D, Xie D, Pernes T, Lewis J, Yang YX. Are patients with inflammatory bowel disease at an increased risk of developing SARS-CoV-2 than patients without inflammatory bowel disease? results from a nationwide veterans’ affairs cohort study. Am J Gastroenterol. 2021;116:808–810.CrossRef
4.
Zurück zum Zitat Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:1575-1578 e1574.CrossRef Singh S, Khan A, Chowdhry M, Bilal M, Kochhar GS, Clarke K. Risk of severe coronavirus disease 2019 in patients with inflammatory bowel disease in the United States: a multicenter research network study. Gastroenterology. 2020;159:1575-1578 e1574.CrossRef
5.
Zurück zum Zitat Ungaro RC, Brenner EJ, Gearry RB et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70:725–732.CrossRef Ungaro RC, Brenner EJ, Gearry RB et al. Effect of IBD medications on COVID-19 outcomes: results from an international registry. Gut. 2021;70:725–732.CrossRef
7.
Zurück zum Zitat Bezzio C, Saibeni S, Variola A et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69:1213–1217.CrossRef Bezzio C, Saibeni S, Variola A et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020;69:1213–1217.CrossRef
8.
Zurück zum Zitat D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock. Clin Gastroenterol Hepatol. 2020;18:2689–2700.CrossRef D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock. Clin Gastroenterol Hepatol. 2020;18:2689–2700.CrossRef
Metadaten
Titel
Covid-19 and Patients with IBD: Who Is at Highest Risk for Severe Complications?
verfasst von
Sara Horst
Publikationsdatum
28.06.2021
Verlag
Springer US
Schlagwort
COVID-19
Erschienen in
Digestive Diseases and Sciences / Ausgabe 4/2022
Print ISSN: 0163-2116
Elektronische ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-021-07106-y

Weitere Artikel der Ausgabe 4/2022

Digestive Diseases and Sciences 4/2022 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.